Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

G. L. Uy; L. J. Costa; P. N. Hari; M. J. Zhang; J. X. Huang; K. C. Anderson; C. N. Bredeson; N. S. Callander; R. F. Cornell; M. A.D. Perez; A. Dispenzieri; C. O. Freytes; R. P. Gale; A. Garfall; M. A. Gertz; J. Gibson; M. Hamadani; H. M. Lazarus; M. E. Kalaycio; R. T. Kamble; M. A. Kharfan-Dabaja; A. Y. Krishnan; S. K. Kumar; R. A. Kyle; H. J. Landau; C. H. Lee; A. Maiolino; D. I. Marks; T. M. Mark; R. Munker; T. Nishihori; R. F. Olsson; M. Ramanathan; T. E. Rodriguez; A. A. Saad; B. N. Savani; G. J. Schiller; H. C. Schouten; J. R. Schriber; E. Scott; S. Seo; M. Sharma; S. Ganguly; E. A. Stadtmauer; J. Tay; L. B. To; D. H. Vesole; D. T. Vogl; J. L. Wagner; B. Wirk; W. A. Wood; A. D'Souza

doi:10.1038/bmt.2015.190

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

G. L. Uy
, L. J. Costa
, P. N. Hari
, M. J. Zhang
, J. X. Huang
, K. C. Anderson
, C. N. Bredeson
, N. S. Callander
, R. F. Cornell
, M. A.D. Perez
, A. Dispenzieri
, C. O. Freytes
, R. P. Gale
, A. Garfall
, M. A. Gertz
, J. Gibson
, M. Hamadani
, H. M. Lazarus
, M. E. Kalaycio
, R. T. Kamble

M. A. Kharfan-Dabaja, A. Y. Krishnan, S. K. Kumar, R. A. Kyle, H. J. Landau, C. H. Lee, A. Maiolino, D. I. Marks, T. M. Mark, R. Munker, T. Nishihori, R. F. Olsson, M. Ramanathan, T. E. Rodriguez, A. A. Saad, B. N. Savani, G. J. Schiller, H. C. Schouten, J. R. Schriber, E. Scott, S. Seo, M. Sharma, S. Ganguly, E. A. Stadtmauer, J. Tay, L. B. To, D. H. Vesole, D. T. Vogl, J. L. Wagner, B. Wirk, W. A. Wood, A. D'Souza

Producción científica: Article › revisión exhaustiva

36 Citas (Scopus)

Resumen

In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

Idioma original	English
Páginas (desde-hasta)	1513-1518
Número de páginas	6
Publicación	Bone Marrow Transplantation
Volumen	50
N.º	12
DOI	https://doi.org/10.1038/bmt.2015.190
Estado	Published - dic 1 2015

Nota bibliográfica

Publisher Copyright:
© 2015 Macmillan Publishers Limited.

Financiación

The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children’s Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick’s Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.

Financiadores	Número del financiador
Allos Therapeutics, Inc.
National Institutes of Health (NIH)
Office of Naval Research Naval Academy
U.S. Department of Health and Human Services	N00014-13-1-0039, N00014-14-1-0028
National Heart, Lung, and Blood Institute (NHLBI)	U10HL069294
National Childhood Cancer Registry – National Cancer Institute	U24CA076518
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...	HHSH250201200016C
Health Resources and Services Administration
National Institute for Health Research Health Protection Research Unit
Actinium Pharmaceuticals Incorporated

ASJC Scopus subject areas

Hematology
Transplantation

Acceder al documento

10.1038/bmt.2015.190

Otros archivos y enlaces

Citar esto

Uy, G. L., Costa, L. J., Hari, P. N., Zhang, M. J., Huang, J. X., Anderson, K. C., Bredeson, C. N., Callander, N. S., Cornell, R. F., Perez, M. A. D., Dispenzieri, A., Freytes, C. O., Gale, R. P., Garfall, A., Gertz, M. A., Gibson, J., Hamadani, M., Lazarus, H. M., Kalaycio, M. E., ... D'Souza, A. (2015). Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 50(12), 1513-1518. https://doi.org/10.1038/bmt.2015.190

@article{1a113a90f3df443c8f4184299ee5a9b6,

title = "Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation",

abstract = "In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 {\texttimes} 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 {\texttimes} 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43\% (95\% confidence interval (CI) 38-48) in GF and 40\% (95\% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82\% (95\% CI 78-86) vs 80\% (95\% CI 75-84), P=0.43 and adjusted 5-year OS was 62\% (95\% CI 54-68) vs 60\% (95\% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.",

author = "Uy, \{G. L.\} and Costa, \{L. J.\} and Hari, \{P. N.\} and Zhang, \{M. J.\} and Huang, \{J. X.\} and Anderson, \{K. C.\} and Bredeson, \{C. N.\} and Callander, \{N. S.\} and Cornell, \{R. F.\} and Perez, \{M. A.D.\} and A. Dispenzieri and Freytes, \{C. O.\} and Gale, \{R. P.\} and A. Garfall and Gertz, \{M. A.\} and J. Gibson and M. Hamadani and Lazarus, \{H. M.\} and Kalaycio, \{M. E.\} and Kamble, \{R. T.\} and Kharfan-Dabaja, \{M. A.\} and Krishnan, \{A. Y.\} and Kumar, \{S. K.\} and Kyle, \{R. A.\} and Landau, \{H. J.\} and Lee, \{C. H.\} and A. Maiolino and Marks, \{D. I.\} and Mark, \{T. M.\} and R. Munker and T. Nishihori and Olsson, \{R. F.\} and M. Ramanathan and Rodriguez, \{T. E.\} and Saad, \{A. A.\} and Savani, \{B. N.\} and Schiller, \{G. J.\} and Schouten, \{H. C.\} and Schriber, \{J. R.\} and E. Scott and S. Seo and M. Sharma and S. Ganguly and Stadtmauer, \{E. A.\} and J. Tay and To, \{L. B.\} and Vesole, \{D. H.\} and Vogl, \{D. T.\} and Wagner, \{J. L.\} and B. Wirk and Wood, \{W. A.\} and A. D'Souza",

note = "Publisher Copyright: {\textcopyright} 2015 Macmillan Publishers Limited.",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/bmt.2015.190",

language = "English",

volume = "50",

pages = "1513--1518",

number = "12",

}

Uy, GL, Costa, LJ, Hari, PN, Zhang, MJ, Huang, JX, Anderson, KC, Bredeson, CN, Callander, NS, Cornell, RF, Perez, MAD, Dispenzieri, A, Freytes, CO, Gale, RP, Garfall, A, Gertz, MA, Gibson, J, Hamadani, M, Lazarus, HM, Kalaycio, ME, Kamble, RT, Kharfan-Dabaja, MA, Krishnan, AY, Kumar, SK, Kyle, RA, Landau, HJ, Lee, CH, Maiolino, A, Marks, DI, Mark, TM, Munker, R, Nishihori, T, Olsson, RF, Ramanathan, M, Rodriguez, TE, Saad, AA, Savani, BN, Schiller, GJ, Schouten, HC, Schriber, JR, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, EA, Tay, J, To, LB, Vesole, DH, Vogl, DT, Wagner, JL, Wirk, B, Wood, WA & D'Souza, A 2015, 'Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation', Bone Marrow Transplantation, vol. 50, n.º 12, pp. 1513-1518. https://doi.org/10.1038/bmt.2015.190

TY - JOUR

T1 - Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

AU - Uy, G. L.

AU - Costa, L. J.

AU - Hari, P. N.

AU - Zhang, M. J.

AU - Huang, J. X.

AU - Anderson, K. C.

AU - Bredeson, C. N.

AU - Callander, N. S.

AU - Cornell, R. F.

AU - Perez, M. A.D.

AU - Dispenzieri, A.

AU - Freytes, C. O.

AU - Gale, R. P.

AU - Garfall, A.

AU - Gertz, M. A.

AU - Gibson, J.

AU - Hamadani, M.

AU - Lazarus, H. M.

AU - Kalaycio, M. E.

AU - Kamble, R. T.

AU - Kharfan-Dabaja, M. A.

AU - Krishnan, A. Y.

AU - Kumar, S. K.

AU - Kyle, R. A.

AU - Landau, H. J.

AU - Lee, C. H.

AU - Maiolino, A.

AU - Marks, D. I.

AU - Mark, T. M.

AU - Munker, R.

AU - Nishihori, T.

AU - Olsson, R. F.

AU - Ramanathan, M.

AU - Rodriguez, T. E.

AU - Saad, A. A.

AU - Savani, B. N.

AU - Schiller, G. J.

AU - Schouten, H. C.

AU - Schriber, J. R.

AU - Scott, E.

AU - Seo, S.

AU - Sharma, M.

AU - Ganguly, S.

AU - Stadtmauer, E. A.

AU - Tay, J.

AU - To, L. B.

AU - Vesole, D. H.

AU - Vogl, D. T.

AU - Wagner, J. L.

AU - Wirk, B.

AU - Wood, W. A.

AU - D'Souza, A.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

AB - In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

UR - https://www.scopus.com/pages/publications/84949085500

UR - https://www.scopus.com/pages/publications/84949085500#tab=citedBy

U2 - 10.1038/bmt.2015.190

DO - 10.1038/bmt.2015.190

M3 - Article

C2 - 26301967

AN - SCOPUS:84949085500

SN - 0268-3369

VL - 50

SP - 1513

EP - 1518

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 12

ER -

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto